| Prolactin and autoimmunity S Shelly, M Boaz, H Orbach Autoimmunity reviews 11 (6-7), A465-A470, 2012 | 296 | 2012 |
| Autonomic dysfunction following COVID-19 infection: an early experience K Shouman, G Vanichkachorn, WP Cheshire, MD Suarez, S Shelly, ... Clinical Autonomic Research 31, 385-394, 2021 | 262 | 2021 |
| Thymoma and autoimmunity S Shelly, N Agmon-Levin, A Altman, Y Shoenfeld Cellular & molecular immunology 8 (3), 199-202, 2011 | 229 | 2011 |
| Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy S Shelly, JD Triplett, MV Pinto, M Milone, FE Diehn, A Zekeridou, ... Brain communications 2 (2), fcaa181, 2020 | 64 | 2020 |
| Epidemiology and natural history of inclusion body myositis: a 40-year population-based study S Shelly, MM Mielke, J Mandrekar, M Milone, FC Ernste, E Naddaf, ... Neurology 96 (21), e2653-e2661, 2021 | 40 | 2021 |
| Survival and associated comorbidities in inclusion body myositis E Naddaf, S Shelly, J Mandrekar, AM Chamberlain, EM Hoffman, ... Rheumatology 61 (5), 2016-2024, 2022 | 32 | 2022 |
| Neurochondrin neurological autoimmunity S Shelly, TJ Kryzer, L Komorowski, R Miske, MD Anderson, EP Flanagan, ... Neurology: Neuroimmunology & Neuroinflammation 6 (6), e612, 2019 | 29 | 2019 |
| Small fiber neuropathy incidence, prevalence, longitudinal impairments, and disability SA Johnson, K Shouman, S Shelly, P Sandroni, SE Berini, PJB Dyck, ... Neurology 97 (22), e2236-e2247, 2021 | 28 | 2021 |
| Potential neurotoxicity of titanium implants: Prospective, in-vivo and in-vitro study S Shelly, SL Zaltsman, O Ben-Gal, A Dayan, I Ganmore, C Shemesh, ... Biomaterials 276, 121039, 2021 | 23 | 2021 |
| Effect of advanced glycation end products on cognition in older adults with type 2 diabetes: results from a pilot clinical trial R Lotan, I Ganmore, A Livny, N Itzhaki, M Waserman, S Shelly, ... Journal of Alzheimer's Disease 82 (4), 1785-1795, 2021 | 22 | 2021 |
| Neurofascin-155 immunoglobulin subtypes: clinicopathologic associations and neurologic outcomes S Shelly, CJ Klein, PJB Dyck, P Paul, ML Mauermann, SE Berini, B Howe, ... Neurology 97 (24), e2392-e2403, 2021 | 21 | 2021 |
| Neuronal intermediate filament IgGs in CSF: autoimmune axonopathy biomarkers A McKeon, S Shelly, C Zivelonghi, E Basal, D Dubey, E Flanagan, ... Annals of Clinical and Translational Neurology 8 (2), 425-439, 2021 | 21 | 2021 |
| Improving accuracy of myasthenia gravis autoantibody testing by reflex algorithm S Shelly, P Paul, H Bi, D Dubey, M Milone, EJ Sorenson, BA Crum, ... Neurology 95 (22), e3002-e3011, 2020 | 20 | 2020 |
| Contactin-1 autoimmunity: serologic, neurologic, and pathologic correlates D Dubey, JA Honorat, S Shelly, CJ Klein, L Komorowski, JR Mills, ... Neurology: Neuroimmunology & Neuroinflammation 7 (4), e771, 2020 | 19 | 2020 |
| Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis I Pinal-Fernandez, A Quintana, JC Milisenda, M Casal-Dominguez, ... Annals of the rheumatic diseases 82 (6), 829-836, 2023 | 18 | 2023 |
| The CADM2 gene is associated with processing speed performance – evidence among elderly with type 2 diabetes L Greenbaum, R Ravona-Springer, A Livny, S Shelly, I Sharvit-Ginon, ... The World Journal of Biological Psychiatry 20 (7), 577-583, 2019 | 18 | 2019 |
| Incidence and prevalence of immune‐mediated necrotizing myopathy in adults in Olmsted County, Minnesota S Shelly, MM Mielke, P Paul, M Milone, JA Tracy, JR Mills, CJ Klein, ... Muscle & nerve 65 (5), 541-546, 2022 | 14 | 2022 |
| Comparison of immune checkpoint inhibitor-related neuropathies among patients with neuroendocrine and non-neuroendocrine tumours P Chompoopong, A Zekeridou, S Shelly, M Ruff, PJ Dyck, CJ Klein, ... Journal of Neurology, Neurosurgery & Psychiatry 93 (1), 112-114, 2022 | 14 | 2022 |
| Expanding the spectrum of chronic immune sensory polyradiculopathy: CISP-plus S Shelly, K Shouman, P Paul, JN Engelstad, KK Amrami, RJ Spinner, ... Neurology 96 (16), e2078-e2089, 2021 | 12 | 2021 |
| Long term dietary restriction of advanced glycation end-products (AGEs) in older adults with type 2 diabetes is feasible and efficacious-results from a pilot RCT R Lotan, I Ganmore, S Shelly, M Zacharia, J Uribarri, P Beisswenger, ... Nutrients 12 (10), 3143, 2020 | 12 | 2020 |
